Aeglea Biotherapeutics Inc.

Plus: Nurix appoints Julia Gregory as chair, and updates from Valneva, Alto, Cour and Kronos

Plus: Spyre boosts balance sheet with $180M PIPE and Pfizer’s bispecific gains EU approval for multiple myeloma

Plus: CEO, CMO out at Theseus and updates from Zenas, Nanoscope, Immunitas and more

Plus: Cameron Turtle becomes CEO of Spyre, and updates from Ocuphire and Astraveus

Interest is rising in autoimmune disease target TL1A. Here’s why

Backed by Fairmount Funds and Venrock and spun out of Paragon, the young start-up has an experienced CFO and is aiming for familiar targets

Plus: Tourmaline reverse-merging with Talaris, CAR T shows early efficacy in myasthenia gravis, and updates from AltPep, Solve and Intercept

Plus: New commercial head at Valneva, and updates from Aeglea and Viridian 

Plus EMA reviewing therapy for arginase 1 deficiency, and updates from Krystal, Oncopeptides, Kymera and more

Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more